• 1. Is parietin a UV-B or a blue-light screening pigment in the lichen Xanthoria parietina?
  Yngvar Gauslaa,Elin Margrete Ustvedt Photochem. Photobiol. Sci. 2003 2 424
• 2. In vitro and in silico molecular docking studies of Rheum emodi-derived diamagnetic SnO2 nanoparticles and their cytotoxic effects against breast cancer
  Deepika Sharma,Naveen Kumar,Tarang Mehrotra,Naveed Pervaiz,Lokesh Agrawal,Shalini Tripathi,Abhishek Jha,Thanasis Poullikkas,Ravinder Kumar,Lalita Ledwani New J. Chem. 2021 45 1695
• 3. Health functions and structure–activity relationships of natural anthraquinones from plants
  Yu Li,Jian-Guo Jiang Food Funct. 2018 9 6063
• 4. Tetracycline studies. Part IV. Some novel cyclisations through benzophenone carbanions, including a new synthesis of anthraquinones
  Cedric H. Hassall,Barry A. Morgan J. Chem. Soc. Perkin Trans. 1 1973 2853
• 5. Parietin: an efficient photo-screening pigment in vivo with good photosensitizing and photodynamic antibacterial effects in vitro
  Laura R. Comini,F. Eduardo Morán Vieyra,Ricardo A. Mignone,Paulina L. Páez,M. Laura Mugas,Brenda S. Konigheim,José L. Cabrera,Susana C. Nú?ez Montoya,Claudio D. Borsarelli Photochem. Photobiol. Sci. 2017 16 201

• Solvents and Organic Chemicals Organic Compounds Benzenoids Anthracenes Anthraquinones
• Anthraquinones
• Naphthoquinones
• Solvents and Organic Chemicals Organic Compounds Heterocyclic Compounds
• Solvents and Organic Chemicals Organic Compounds Alcohol/Ether

Physcion (CAS No. 521-61-9): A Comprehensive Overview of Its Chemical Profile and Emerging Therapeutic Applications

Physcion, chemically known as 7-hydroxy-6-methyl-8H-dibenzo[α,j]acridine, is a naturally occurring heterocyclic compound with the molecular formula C₁₉H??NO. Its CAS number, CAS No. 521-61-9, uniquely identifies it in the chemical and pharmaceutical industries. This compound has garnered significant attention in recent years due to its diverse pharmacological properties and potential applications in medicinal chemistry and drug development.

The structural framework of Physcion consists of a fused system of two benzene rings connected by a nitrogen atom, forming a dibenzo[α,j]acridine core. This unique scaffold contributes to its remarkable biological activity, making it a subject of extensive research in various therapeutic areas. The presence of a hydroxyl group at the 7-position and a methyl group at the 6-position enhances its interactiveness with biological targets, thereby modulating cellular processes.

Recent studies have highlighted the antimicrobial and anti-inflammatory properties of Physcion. Its ability to inhibit the growth of Gram-positive bacteria and fungi has been attributed to its interaction with bacterial cell wall synthesis and fungal ergosterol pathways. Furthermore, preclinical investigations have demonstrated its potential in modulating inflammatory responses by inhibiting key pro-inflammatory cytokines such as TNF-α and IL-6. These findings suggest that Physcion could be a valuable candidate for developing novel antimicrobial agents and anti-inflammatory therapies.

In addition to its antimicrobial and anti-inflammatory effects, Physcion has shown promise in cancer research. Studies have revealed that it can induce apoptosis in various cancer cell lines by activating caspase-dependent pathways. Its ability to disrupt the mitochondrial membrane potential and enhance reactive oxygen species (ROS) production contributes to its cytotoxic effects. Moreover, Physcion has been found to inhibit the activity of tyrosine kinases, which are crucial in cancer cell proliferation and survival. These mechanisms make it an attractive lead compound for further development into an anticancer therapeutic agent.

The pharmacokinetic profile of Physcion is another area of interest. Research indicates that it exhibits moderate solubility in water and lipids, allowing for versatile administration routes. Its bioavailability can be enhanced by chemical modifications such as prodrug formulations or nanoparticle encapsulation. These advancements are crucial for optimizing its therapeutic efficacy and ensuring targeted delivery to affected tissues.

The synthesis of Physcion remains a challenging yet fascinating aspect of organic chemistry. Traditional methods involve multi-step reactions starting from readily available precursors such as benzaldehyde derivatives. However, recent advancements in synthetic methodologies have enabled more efficient and scalable production processes. For instance, catalytic hydrogenation techniques have been employed to simplify the synthesis while maintaining high yields. These improvements are essential for meeting the growing demand for Physcion in both research and industrial applications.

The safety profile of Physcion is another critical consideration in its development as a therapeutic agent. Preliminary toxicology studies have shown that it exhibits low toxicity at therapeutic doses, with minimal side effects observed in animal models. However, further long-term studies are necessary to fully assess its safety profile in humans. Collaborative efforts between chemists, pharmacologists, and clinicians are essential for ensuring that Physcion-based therapies are both effective and safe for clinical use.

The future prospects of Physcion in pharmaceutical development are promising. Ongoing research aims to explore its potential applications in neurodegenerative diseases, where its ability to modulate neurotransmitter pathways could be beneficial. Additionally, its antimicrobial properties make it a candidate for addressing antibiotic-resistant infections, a growing global health concern. As our understanding of its mechanisms of action continues to evolve, so too will its therapeutic potential.

In conclusion, Physcion (CAS No. 521-61-9) is a multifaceted compound with significant potential in various therapeutic areas. Its unique chemical structure, coupled with its diverse biological activities, positions it as a valuable asset in medicinal chemistry and drug development. Continued research efforts will be essential for unlocking its full therapeutic potential and translating these findings into effective treatments for human diseases.

• 4517-57-1(3-Formyl-1,8-dihydroxy-6-methoxyanthrachinon)
• 73726-67-7(1,4,5-trihydroxy-7-methoxy-2,3-dimethylanthracene-9,10-dione)
• 111228-19-4(1,8-dihydroxy-6-methoxy-2-methyl-anthraquinone)
• 22225-63-4(9,10-Anthracenedione,1-hydroxy-3-methoxy-6-methyl-)
• 476-57-3(9,10-Anthracenedione,1,4,5-trihydroxy-7-methoxy-2-methyl-)
• 57754-80-0(1,8-Dihydroxy-3-methoxy-anthrachinon)
• 1215751-27-1(Physcion-d)
• 22225-67-8(Macrosporin)
• 3571-31-1(1,8-dihydroxy-3-methoxy-6-methylanthracen-9(10H)-one)
• 148918-78-9(9,10-Anthracenedione, 1,5-dihydroxy-3-methoxy-7-methyl-)